Literature DB >> 31032068

National practice trends for the surgical management of lung cancer in the CMS population: an atlas of care.

Joseph D Phillips1,2, Ian C Bostock1, Rian M Hasson1,2, Philip P Goodney1,2, David C Goodman1,2, Timothy M Millington1,2, David J Finley1,2.   

Abstract

BACKGROUND: Video-assisted thoracoscopic surgery (VATS) has been established as a safe and effective alternative to an open approach for the treatment of early-stage lung cancer. Despite this, differences in utilization across the nation are present. The aims of this study were to: (I) characterize trends in the use of open surgery and VATS for the management of lung cancer across the United States, and (II) describe if particular regions of the country utilize minimally invasive surgery more frequently.
METHODS: We studied all Medicare beneficiaries from the ages of 65 to 99 years with full Part A and B coverage and no HMO coverage for the years of 2006 and 2014 (the most recent year available at the time of this analysis). Beneficiaries with a diagnosis of lung cancer (ICD-9 codes: 162.0 162.2 162.3 162.4 162.5 162.8 162.9) were selected. Rates of thoracoscopic surgery (CPT codes: 32663, 32666, 32667, 32668, 32669, 32670, 32671) and open lung resections (32505, 32506, 32507, 32608, 32440, 32442, 32445, 32480, 32482, 32484, 32486, 32488) were calculated by year and region. Rates in 2006 and 2014 with descriptive statistics and a univariate analysis were performed using Student's t-test and chi-square, as appropriate. A two-sided P value <0.05 was considered statistically significant.
RESULTS: A total of 24,368,333 and 23,921,059 beneficiaries for the years of 2006 and 2014 were analyzed. A diagnosis of lung cancer was detected in claims of 167,418 patients (0.7%) in 2006 and 167,506 patients in 2014 (0.7%), which was not significantly different (P=0.7). Among these lung cancer patients, a surgical intervention was performed in 17,249 patients (10.3%) during 2006 and 18,603 patients (11.1%) in 2014 (P=0.01). Among those undergoing surgery, a VATS approach was performed in 2,512 patients (15%) during 2006 and 9,578 patients (54%) during 2014 (P=0.001). In 2006, California, New York, and New Jersey performed the most VATS procedures, in comparison to 2014, when New York, Florida, and California performed the highest number of VATS procedures.
CONCLUSIONS: While the prevalence of lung cancer in the United States was unchanged between 2006 and 2014, the use of VATS techniques increased five-fold. Further studies to better understand the adoption or availability of new surgical techniques in lung cancer populations across geographic regions and patient populations are necessary.

Entities:  

Keywords:  Lung cancer; minimally invasive techniques; practice trends; thoracoscopy

Year:  2019        PMID: 31032068      PMCID: PMC6465423          DOI: 10.21037/jtd.2019.01.05

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN: 2072-1439            Impact factor:   2.895


  28 in total

1.  New Dartmouth Atlas: improving US cardiac care?

Authors:  L Newman
Journal:  Lancet       Date:  2000-08-19       Impact factor: 79.321

2.  Dartmouth Atlas of Vascular Health Care review: impact of hospital volume, surgeon volume, and training on outcome.

Authors:  T S Huber; J M Seeger
Journal:  J Vasc Surg       Date:  2001-10       Impact factor: 4.268

3.  The Dartmouth Atlas of Health Care: what is it telling us?

Authors:  M M Cooper
Journal:  Health Syst Rev       Date:  1996 May-Jun

4.  The influence of hospital volume on survival after resection for lung cancer.

Authors:  P B Bach; L D Cramer; D Schrag; R J Downey; S E Gelfand; C B Begg
Journal:  N Engl J Med       Date:  2001-07-19       Impact factor: 91.245

5.  Associations between hospital and surgeon procedure volumes and patient outcomes after ovarian cancer resection.

Authors:  Deborah Schrag; Craig Earle; Feng Xu; Katherine S Panageas; K Robin Yabroff; Robert E Bristow; Edward L Trimble; Joan L Warren
Journal:  J Natl Cancer Inst       Date:  2006-02-01       Impact factor: 13.506

6.  Changes in the use of carotid revascularization among the medicare population.

Authors:  Philip P Goodney; F Lee Lucas; Lori L Travis; Donald S Likosky; David J Malenka; Elliott S Fisher
Journal:  Arch Surg       Date:  2008-02

7.  Surgeon volume compared to hospital volume as a predictor of outcome following primary colon cancer resection.

Authors:  Deborah Schrag; Katherine S Panageas; Elyn Riedel; Lillian Hsieh; Peter B Bach; Jose G Guillem; Colin B Begg
Journal:  J Surg Oncol       Date:  2003-06       Impact factor: 3.454

8.  Lobectomy by video-assisted thoracic surgery (VATS) versus thoracotomy for lung cancer.

Authors:  Raja M Flores; Bernard J Park; Joseph Dycoco; Anna Aronova; Yael Hirth; Nabil P Rizk; Manjit Bains; Robert J Downey; Valerie W Rusch
Journal:  J Thorac Cardiovasc Surg       Date:  2009-07       Impact factor: 5.209

9.  Video-assisted thoracic surgery lobectomy: report of CALGB 39802--a prospective, multi-institution feasibility study.

Authors:  Scott J Swanson; James E Herndon; Thomas A D'Amico; Todd L Demmy; Robert J McKenna; Mark R Green; David J Sugarbaker
Journal:  J Clin Oncol       Date:  2007-11-01       Impact factor: 44.544

10.  Thoracoscopic lobectomy: report on safety, discharge independence, pain, and chemotherapy tolerance.

Authors:  Daniel G Nicastri; Juan P Wisnivesky; Virginia R Litle; Jaime Yun; Cynthia Chin; Francine R Dembitzer; Scott J Swanson
Journal:  J Thorac Cardiovasc Surg       Date:  2008-03       Impact factor: 5.209

View more
  2 in total

Review 1.  A brief overview of thoracic surgery in the United States.

Authors:  Catherine T Byrd; Kiah M Williams; Leah M Backhus
Journal:  J Thorac Dis       Date:  2022-01       Impact factor: 3.005

2.  Early Outcomes of Robotic Versus Video-Assisted Thoracoscopic Anatomical Resection for Lung Cancer.

Authors:  Ji Hyeon Park; Samina Park; Chang Hyun Kang; Bub Se Na; So Young Bae; Kwon Joong Na; Hyun Joo Lee; In Kyu Park; Young Tae Kim
Journal:  J Chest Surg       Date:  2022-02-05
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.